Featured articles
Latest news
People with CIDP reveal treatment priorities
Qualitative study suggests that weakness and fatigue are the top treatment priorities for people with CIDP.
Early severity of hives may signal chronicity
Findings suggest that children exhibiting more severe symptoms during the first week of an AU episode may be at increased risk of developing CSU.
Tolebrutinib potential in MS: Phase 3 trials
News article on phase 3 data of tolebrutinib compared with placebo and teriflunomide in multiple sclerosis from HERCULES, GEMINI 1, and GEMINI 2.
Real-world data clarify IVIg safety in CIDP
Study suggests that thrombotic events, acute kidney injury, and hemolytic events are rare among people with CIDP receiving IVIg.
API-CAT supports extended reduced-dose apixaban
API-CAT: Extended anticoagulation with reduced-dose apixaban results in similar VTE risk and reduced bleeding risk in patients with CAT.
ZUMA-12: Axi-cel shows durable response in LBCL
First-line axicabtagene ciloleucel (axi-cel) shows high rates of complete and durable responses in high-risk large B-cell lymphoma (LBCL).
